Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo
ESMO Congress 2022
Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's my pleasure to speak about DeFi phase III trial of nirogacestat in progressing desmoid tumor patients and I had the pleasure to present that trial yesterday at ESMO 2022 in the presidential session.
When talking about desmoid tumors, we are actually talking about a rare disease. They are locally aggressive and invasive soft tissue tumors that are somehow difficult to manage due to their variable presentations, the unpredictable clinical cause, and the lack of currently approved therapies. There is indeed a clear rationale for the use of gamma secretase inhibitors in this disease as desmoid tumors express [inaudible 00:00:47], which can be blocked by gamma secretase inhibitors.
So nirogacestat is an investigational oral and selective small molecule gamma secretase inhibitor that already showed activity in phase I and II trials in desmoid tumors with a manageable safety profile. The phase III trial is a large global randomized double blind placebo-controlled trial, looking at safety, efficacy and tolerability of nirogacestat in comparison to placebo in resist progressing desmoid tumors.
We actually randomized 142 patients in 37 sites all over the world and primary endpoint was progression-free survival and secondary endpoints included overall response rate, and a couple of different patient-reported outcome measures.
So the results are as follows. The primary endpoint was met with improved progression-free survival, demonstrating a statistically significant 71% reduction in the risk of disease progression. And the confirmed objective response rate was 41% with nirogacestat as compared to 8% in the placebo arm. Again, highly statistically significant, including 7% complete responses with nirogacestat. The median time to response was 5.6 months with nirogacestat compared to 11 month in the placebo arm.
In terms of safety, actually nirogacestat was well tolerated. 95% of all treatment emergent adverse events were grade I or II. The most frequent side effect with nirogacestat were diarrhea, rash, hyperphosphatemia and fatigue. And those reductions were necessary in about 40% of patients and were primarily due to diarrhea, rash, and stomatitis.
In summary, DeFi represents the largest and most rigorous randomized controlled trial to-date in desmoid tumor. It actually definitely showed rapid, sustained and statistically significant improvements in all primary and secondary endpoints. It had a manageable safety profile with 95% of all the treatment emergent adverse events being grade I or II, and nirogacestat does have the potential to become the standard of care in desmoid tumors requiring systemic treatment.
There are definitely a couple of open questions still from that trial. One question might be the lengths of treatment duration so there could be something like a discontinuation trial. But what we'd learned from that trial already that nirogacestat is absolutely feasible for long-term treatment in this patient population and we will investigate, of course, a lot of other questions as well.
Related Videos
The ASCO Post Staff
Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.
The ASCO Post Staff
Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA biomarkers may help to identify patients who may benefit from enzalutamide treatment compared with active surveillance (Abstract 1385P).
The ASCO Post Staff
Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).
The ASCO Post Staff
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).
The ASCO Post Staff
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).
